Compare MNPR & NPFD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | MNPR | NPFD |
|---|---|---|
| Founded | 2014 | N/A |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Trusts Except Educational Religious and Charitable |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 372.9M | 474.6M |
| IPO Year | 2019 | 2021 |
| Metric | MNPR | NPFD |
|---|---|---|
| Price | $55.74 | $19.17 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 13 | 0 |
| Target Price | ★ $101.42 | N/A |
| AVG Volume (30 Days) | ★ 150.5K | 63.8K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $26.06 | $16.79 |
| 52 Week High | $105.00 | $20.12 |
| Indicator | MNPR | NPFD |
|---|---|---|
| Relative Strength Index (RSI) | 45.47 | 30.34 |
| Support Level | $56.15 | $18.93 |
| Resistance Level | $61.30 | $19.29 |
| Average True Range (ATR) | 3.32 | 0.20 |
| MACD | 0.75 | -0.08 |
| Stochastic Oscillator | 53.45 | 13.64 |
Monopar Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing proprietary therapeutics designed to extend life or improve the quality of life for cancer patients. The company's pipeline consists of Validive for the prevention of chemoradiotherapy-induced severe oral mucositis in oropharyngeal cancer patients, camsirubicinfor the treatmentof soft tissue sarcoma, a late-stage preclinical antibody, MNPR-101, for cancers and severe COVID-19 and an early-stage camsirubicin analog, MNPR-202, for various cancers.
Nuveen Variable Rate Preferred&Income is a diversified, closed-end management investment company. Its investment objective is to provide a high level of current income and total return. The fund invests a majority of its assets in variable-rate preferred securities and other variable-rate income-producing securities. The rest of its investments can be made in contingent capital securities or contingent convertible securities, convertible securities, corporate debt securities, U.S. government securities, residential and commercial mortgage-backed securities, fixed-rate preferred securities, senior loans and loan participations and assignments, sovereign debt instruments, debt securities issued by supranational agencies, and/or taxable and tax-exempt municipal bonds.